Atreleuton (also known as MK-886) is a potent inhibitor of the 5-lipoxygenase-activating protein (FLAP), which blocks the production of leukotrienes, key inflammatory mediators. It is primarily utilized in pharmaceutical research and preclinical studies for investigating inflammatory pathways in conditions such as asthma, rheumatoid arthritis, and other chronic inflammatory diseases. By reducing leukotriene synthesis, it helps alleviate symptoms like airway constriction, swelling, and pain in experimental models. Atreleuton is also explored in research on cardiovascular diseases, including atherosclerosis, due to the role of leukotrienes in these processes. As an investigational compound not approved for clinical use, it is mainly employed in laboratory settings to study leukotriene biology and develop novel anti-inflammatory therapies.